Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Selective serotonin reuptake inhibitors
19 evidence topics · 11 sources
NICE guideline: an SSRI as the first drug treatment, with sertraline first
NICE guideline: precautions with SSRIs
WFSBP guideline: SSRIs and SNRIs as first-line medications
CANMAT guideline: first-line, second-line, and third-line agents
“Agomelatine, duloxetine, escitalopram, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Citalopram, divalproex chrono, fluoxetine, mirtazapine, trazodone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: SSRIs as first-line pharmacological treatment
U.S. primary care review: SSRIs and SNRIs as first-line medications
FDA-approved GAD indication: escitalopram
FDA-approved GAD indication: paroxetine
FDA-approved agents and SSRIs without a GAD indication
“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram has been approved by the FDA for the treatment of GAD in adults, and both escitalopram and citalopram have been evaluated in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a double-blind, placebo-controlled maintenance study, patients were treated with fixed-dose escitalopram (20 mg/day) over the course of 24–76 weeks, and re-randomization to placebo was associated with a significantly higher risk of relapse (OR: 4; 56% vs. 19%; log-rank test, p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: escitalopram, sertraline, fluoxetine, and paroxetine
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Primary outcomes were efficacy (mean difference [MD] in change in Hamilton Anxiety Scale Score) and acceptability (study discontinuations for any cause).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of SSRIs, SNRIs, and benzodiazepines against placebo: effect sizes and response rates
“A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Side effects of SSRIs during the initial weeks of treatment include nausea, dizziness, headaches, jitteriness, sleep difficulties, and gastrointestinal disturbances.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Escitalopram compared with paroxetine: adverse events and discontinuation
“A second and longer study (24 weeks) involved double-blind treatment with escitalopram (n=60; 10–20 mg/day) or paroxetine (n=61; 20–0 mg/day) and, while no differences were observed with regard to improvement in anxiety symptoms, treatment-emergent adverse events were more frequent in paroxetine-treated patients compared to those randomized to escitalopram (88.7% vs. 77.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, significantly fewer escitalopram- compared to paroxetine-treated patients discontinued due to adverse events (6.6% vs. 22.6%; p=0.02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions with escitalopram in adult GAD trials
Adverse reactions with paroxetine in adult GAD trials
Boxed warning and discontinuation syndrome in SSRI labeling
BAP guideline: adverse effects and discontinuation syndrome with SSRIs
Relapse after discontinuation: meta-analysis of relapse prevention trials, SSRI subgroup
| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
|---|---|---|
| All anxiety disorders | “28”View highlighted excerpt for this quote | “3.11 (2.48 to 3.89)”View highlighted excerpt for this quote |
| Generalised anxiety disorder (DSM-IV) | “6”View highlighted excerpt for this quote | “4.20 (2.42 to 7.28)”View highlighted excerpt for this quote |
| SSRI | “21”View highlighted excerpt for this quote | “2.86 (2.17 to 3.78)”View highlighted excerpt for this quote |